Back to Search
Start Over
Coenzyme Q0 From Antrodia cinnamomea Exhibits Drug-Resistant Bacteria Eradication and Keratinocyte Inflammation Mitigation to Ameliorate Infected Atopic Dermatitis in Mouse.
- Source :
- Frontiers in Pharmacology; 12/3/2019, Vol. 10, p1-16, 16p
- Publication Year :
- 2019
-
Abstract
- Atopic dermatitis (AD) is an inflammatory skin disease that is usually accompanied by Staphylococcus aureus infection due to cutaneous barrier-function damage. Benzenoid compounds from Antrodia cinnamomea are known to exhibit antibacterial and anti-inflammatory activities. This study sought to investigate the potential of benzenoids for treating bacteria-infected AD. The compounds were screened against methicillin-resistant S. aureus (MRSA). Coenzyme Q<subscript>0</subscript> (CoQ<subscript>0</subscript>), a key ingredient in A. cinnamomea , showed the strongest MRSA growth inhibition. We further tested the inhibitory effect of CoQ<subscript>0</subscript> on planktonic and biofilm MRSA. The work was also performed to explore the potential effectiveness of CoQ<subscript>0</subscript> on AD using activated keratinocytes and in vivo experimental AD mice as the models. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of CoQ<subscript>0</subscript> against MRSA were 7.81 μg/ml. CoQ<subscript>0</subscript> was found to eradicate biofilm MRSA efficiently and reduce the biofilm thickness. CoQ<subscript>0</subscript> killed MRSA by inhibiting DNA polymerase and topoisomerases. A proteomic assay showed that CoQ<subscript>0</subscript> also reduced the ribosomal proteins. In the anti-inflammation study, CoQ<subscript>0</subscript> was found to downregulate the expression of interleukin (IL)-6, chemokine (C-C motif) ligand (CCL)5, and CCL17 in HaCaT cells. CoQ<subscript>0</subscript> at 0.5 μg/ml could recover the filaggrin decreased by HaCaT activation to the normal control. We established a bacteria-infected AD-like model in mice using ovalbumin (OVA) and topically applied MRSA. Topical CoQ<subscript>0</subscript> delivery lessened the MRSA presence in the AD-like lesions by >90%. The erythema, barrier function, and epidermal thickness of the AD-like wounds were improved by CoQ<subscript>0</subscript> through the reduction of IL-1β, IL-4, IL-6, IL-10, interferon (IFN)-γ, and by neutrophil infiltration in the lesional skin. CoQ<subscript>0</subscript> is therefore regarded as effective in mitigating AD symptoms associated with bacterial load. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 16639812
- Volume :
- 10
- Database :
- Complementary Index
- Journal :
- Frontiers in Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 140083397
- Full Text :
- https://doi.org/10.3389/fphar.2019.01445